Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Pfizer Gets Patent for New HIV/AIDS Drug in India, Says Report

December 11, 2007

According to a report on the Web site of the Business Standard, the Bombay Patent Office has granted Pfizer a patent on its new AIDS drug Selzentry (maraviroc). Quoting a spokesperson of Pfizer India, the newspaper said the patent had been issued, and the company is in the process of complying with regulations for its registration.

Under development by Pfizer scientists for 10 years, the medication, the first in a new class of HIV/AIDS drugs, works by blocking HIV's entry into cells. The U.S. Food and Drug Administration approved Selzentry in August, and the European Commission did so in September.

This is the latest development in a series of struggles between multinationals, who want patent protection in the Indian market, and patients' advocates, who say millions of poor people will be affected by decisions that determine the drugs' pricing and availability.

Advertisement
"We are committed to bringing meaningful improvement to the lives of people living with and those at risk of HIV/AIDS through outreach programs that will enable access to innovative medicines to patients," the Pfizer India spokesperson said.

Back to other news for December 2007

Adapted from:
Deutsche Presse-Agentur
12.11.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement